Daniel Marbach

15PUBLICATIONS
148CO-AUTHORS
Molecular targetsTumour immunologyNanotoxicology, health and safetyBioinformatic methods developmentCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 13, 2026
A Randomized, Nivolumab-controlled, Phase 2 and Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus.

|Jul 03, 2026
Generalizable AI predicts immunotherapy outcomes across cancers and treatments.

|Apr 07, 2026
A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1-LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma.

Elena Garralda, Christoph Markert, Victor Moreno

|Sep 24, 2025
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial.

Georgina V Long, Nitya Nair, Daniel Marbach

|May 19, 2025
Generalizable AI predicts immunotherapy outcomes across cancers and treatments.

Wanxiang Shen, Thinh H Nguyen, Michelle M Li

|May 15, 2025
A microfluidic bone marrow chip for the safety profiling of biologics in pre-clinical drug development.

Leopold Koenig, Laurent Juglair, Thi Phuong Tao

Pageof 3

Frequent Collaborators

4 joint publications

Marinka Zitnik

3 joint publications

Sven Bergmann

3 joint publications

Michelle M Li

2 joint publications

Byoung Chul Cho